A Phase 1, Double Blind, Sponsor Open, Placebo Controlled Combined Single And Multiple Ascending Dose Study To Investigate The Safety, Tolerability And Food Effect On Pharmacokinetics Of PF-06669571 Following Oral Doses In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2015
At a glance
- Drugs PF 6669571 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 16 Apr 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
- 26 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Apr 2015.
- 01 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.